Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has granted stock options to two new employees as employment inducements. The grants total 46,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan, complying with Nasdaq Rule 5635(c)(4).
The options were granted on February 18 and 24, 2025, with exercise prices of $0.83 and $0.8314 per share respectively, matching Context's closing stock prices on those dates. These 10-year options follow a four-year vesting schedule: 25% vests after one year, with the remaining 75% vesting in 36 monthly installments. Vesting is contingent on continued employment with Context.
Context Therapeutics (Nasdaq: CNTX), un'azienda biofarmaceutica focalizzata sui trattamenti per i tumori solidi, ha concesso opzioni su azioni a due nuovi dipendenti come incentivo all'assunzione. Le concessioni ammontano a 46.000 azioni ordinarie, assegnate al di fuori del Piano di Incentivazione per le Prestazioni a Lungo Termine 2021 dell'azienda, in conformità con la Regola 5635(c)(4) di Nasdaq.
Le opzioni sono state concesse il 18 e il 24 febbraio 2025, con prezzi di esercizio di $0.83 e $0.8314 per azione rispettivamente, corrispondenti ai prezzi di chiusura delle azioni di Context in quelle date. Queste opzioni di 10 anni seguono un programma di maturazione di quattro anni: il 25% matura dopo un anno, mentre il restante 75% matura in 36 rate mensili. La maturazione è subordinata al mantenimento dell'impiego presso Context.
Context Therapeutics (Nasdaq: CNTX), una empresa biofarmacéutica centrada en tratamientos para tumores sólidos, ha otorgado opciones sobre acciones a dos nuevos empleados como incentivos para su contratación. Las concesiones totalizan 46,000 acciones ordinarias, otorgadas fuera del Plan de Incentivos de Rendimiento a Largo Plazo 2021 de la empresa, cumpliendo con la Regla 5635(c)(4) de Nasdaq.
Las opciones se otorgaron el 18 y 24 de febrero de 2025, con precios de ejercicio de $0.83 y $0.8314 por acción respectivamente, coincidiendo con los precios de cierre de las acciones de Context en esas fechas. Estas opciones de 10 años siguen un cronograma de adquisición de cuatro años: el 25% se adquiere después de un año, y el 75% restante se adquiere en 36 cuotas mensuales. La adquisición está condicionada a la continuidad del empleo con Context.
Context Therapeutics (Nasdaq: CNTX)는 고형 종양 치료에 집중하는 생명공학 회사로, 두 명의 새로운 직원에게 주식 옵션을 부여했습니다. 이 부여는 46,000주의 보통주로, 회사의 2021년 장기 성과 인센티브 계획 외부에서 수여되었으며, Nasdaq 규칙 5635(c)(4)를 준수합니다.
옵션은 2025년 2월 18일과 24일에 부여되었으며, 각각 $0.83 및 $0.8314의 행사 가격을 가지고 있습니다. 이는 해당 날짜의 Context 주식 마감 가격과 일치합니다. 이 10년 옵션은 4년의 베스팅 일정에 따라 진행됩니다: 1년 후 25%가 베스팅되며, 나머지 75%는 36개월에 걸쳐 월별로 베스팅됩니다. 베스팅은 Context에서의 지속적인 고용에 따라 달라집니다.
Context Therapeutics (Nasdaq: CNTX), une entreprise biopharmaceutique axée sur les traitements des tumeurs solides, a accordé des options d'achat d'actions à deux nouveaux employés en tant qu'incitation à l'embauche. Les attributions totalisent 46 000 actions ordinaires, accordées en dehors du Plan d'Incitation à la Performance à Long Terme 2021 de l'entreprise, conformément à la Règle 5635(c)(4) de Nasdaq.
Les options ont été accordées les 18 et 24 février 2025, avec des prix d'exercice de $0.83 et $0.8314 par action respectivement, correspondant aux prix de clôture des actions de Context à ces dates. Ces options de 10 ans suivent un calendrier d'acquisition de quatre ans : 25 % s'acquièrent après un an, et les 75 % restants s'acquièrent en 36 versements mensuels. L'acquisition est conditionnée à la poursuite de l'emploi chez Context.
Context Therapeutics (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung von soliden Tumoren spezialisiert hat, hat Aktienoptionen vergeben an zwei neue Mitarbeiter als Anreiz zur Einstellung. Die Zuteilungen belaufen sich auf insgesamt 46.000 Aktien des Stammkapitals, die außerhalb des langfristigen Leistungsanreizplans 2021 des Unternehmens gewährt wurden und die Nasdaq-Regel 5635(c)(4) einhalten.
Die Optionen wurden am 18. und 24. Februar 2025 mit Ausübungspreisen von $0.83 und $0.8314 pro Aktie gewährt, was den Schlusskursen der Context-Aktien an diesen Tagen entspricht. Diese 10-Jahres-Optionen folgen einem vierjährigen Vesting-Zeitplan: 25% werden nach einem Jahr fällig, während die verbleibenden 75% in 36 monatlichen Raten fällig werden. Das Vesting ist an die Fortsetzung der Anstellung bei Context gebunden.
- None.
- None.
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 46,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted to the new employees on their respective hire dates (February 18, 2025 and February 24, 2025) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date (
The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the potential benefits, characteristics, safety and side effect profile of our product candidates, (ii) the likelihood data will support future development of our product candidates, and (iii) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
FAQ
How many shares were included in Context Therapeutics' (CNTX) February 2025 inducement grants?
What is the vesting schedule for CNTX's February 2025 inducement stock options?
What were the exercise prices for CNTX's February 2025 inducement grants?
How long is the term of CNTX's February 2025 inducement stock options?
